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Melanoma-associated antigen-encoding (MAGE) genes are expressed in melanoma and other cancers but not in
normal somatic cells. MAGE expression is associated with aggressive tumor growth, poor clinical outcome, and
resistance to chemotherapy, but the mechanisms have not been completely elucidated. In this study, we show
that downregulation of MAGE-C2 in A375 melanoma cells and low-passage cultures from human metastatic
melanomas (MRA cells) results in increased apoptosis and decreased growth of tumor xenografts in athymic
nude mice. Previously, we showed that MAGE-C2 binds KAP1, a scaffolding protein that regulates DNA repair.
Phosphorylation of KAP1-Serine 824 (Ser824) by ataxia-telangiectasia–mutated (ATM) kinase is necessary for repair
of DNA double-strand breaks (DSBs); now we show that MAGE-C2 knockdown reduces, whereas MAGE-C2
overexpression increases, ATM kinase–dependent phosphorylation of KAP1-Ser824. We demonstrate that MAGE-
C2 increases co-precipitation of KAP1 with ATM and that binding of MAGE-C2 to KAP1 is necessary for increased
KAP1-Ser824 phosphorylation. Furthermore, ectopic expression of MAGE-C2 enhances repair of I-SceI
endonuclease–induced DSBs in U-2OS cells. As phosphorylation of KAP1-Ser824 facilitates relaxation of
heterochromatin, which is necessary for DNA repair and cellular proliferation, our results suggest that MAGE-
C2 can promote tumor growth by phosphorylation of KAP1-Ser824 and by enhancement of DNA damage repair.
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INTRODUCTION
Melanoma is the most deadly form of skin cancer, accounting
for o5% of skin cancer cases but for more than 75% of skin
cancer deaths. Unlike other common types of cancers, the
incidence of melanoma continues to rise and the American
Cancer Society estimates that B114,900 new cases of
melanoma were diagnosed in the United States in 2010—
46,770 noninvasive (in situ) and 68,l30 invasive—with nearly
8,700 resulting in death (Surveillance, Epidemiology, and End
Results Program and the National Center for Health Statistics,
http://www.skincancer.org/Skin-Cancer-Facts/#melanoma).
The first melanoma-associated antigen-encoding (MAGE)
gene was identified in melanoma in 1991 as a gene encoding
tumor-specific antigens recognized by cytolytic T lymphocytes
(Chomez et al., 2001). MAGE proteins have been classified
into two subfamilies: MAGE-I and MAGE-II. The MAGE-II
family members are ubiquitously expressed in somatic tissue.
The MAGE-I family members (collectively called MAGE
hereon) are encoded by 28 genes clustered on the X chro-
mosome (Chomez et al., 2001). MAGE proteins are normally
expressed only in developing sperm, trophoblasts, fetal ovarian
germ cells, and placenta (Takahashi et al., 1995; Jungbluth
et al., 2002; Rajpert-De Meyts et al., 2003; Yakirevich et al.,
2003; Gaskell et al., 2004; Pauls et al., 2006; Zhuang et al.,
2006). MAGE I genes are unusual in that their expression is
normally suppressed in all somatic tissues by hypermethy-
lation of promoter region CpG islands (De Smet et al., 1999;
Sigalotti et al., 2004). Genome-wide hypomethylation may
occur in neoplastic transformation and often causes MAGE
protein expression in tumor cells. Thus, MAGE proteins are
peculiar for their absence in normal adult somatic tissues but
are aberrantly expressed in various malignancies, includ-
ing melanoma (Hofbauer et al., 1997; Basarab et al., 1999;
Jungbluth et al., 2000, 2005; Park et al., 2002; Dhodapkar
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et al., 2003; Riker et al., 2008). Recently, MAGE expression
has been identified as an independent prognostic variable
associated with metastasis and extent of relapse-free survival,
comparable to Breslow thickness and ulceration in melanoma
(Svobodova et al., 2011).
KRAB domain–associated protein 1 (KAP1), also known as
TIF1b (transcriptional intermediary factor 1), TRIM28, or Krip1,
is a universal corepressor protein and acts as a molecular
scaffold (Iyengar and Farnham, 2011). KAP1 induces chro-
matin condensation and histone modification, resulting
in repression of specific genes (Groner et al., 2010). KAP1
localizes to sites of DNA damage, in a sequence-independent
manner, where it is critical for the DNA repair process
(Goodarzi et al., 2009). Phosphorylation of KAP1-Serine
824 (Ser824) by ataxia-telangiectasia–mutated (ATM) kinase
(Li et al., 2007) initiates and propagates chromatin
relaxation necessary for the repair of damaged DNA (White
et al., 2006; Goodarzi et al., 2008). In addition, KAP1 is
increasingly being recognized as a critical multifunctional
molecule (Monte et al., 2006; Yang et al., 2007; Liu et al.,
2008; Atanackovic et al., 2010; Doyle et al., 2010; Nardiello
et al., 2011). Recently, we and others have shown that
MAGE proteins bind to KAP1, suppress p53 and apoptosis,
and increase tumor survival in vivo (Yang et al., 2007; Doyle
et al., 2010).
MAGE proteins can be considered specific cancer molecu-
lar biomarkers because of their selective expression in cancer
cells and association with aggressive tumor growth, poor
prognosis, and relapse. Although recent studies have sought
to understand the role of MAGE proteins in cancer, the
cellular and physiological functions of MAGE proteins have
not been fully elucidated. In this study, we demonstrate that
MAGE proteins are important factors in the survival and
growth of melanoma cells. Here we establish that MAGE
proteins induce ATM kinase–dependent phosphorylation of
KAP1-Ser824 and promote DNA damage repair, establishing
another mechanism by which Class I MAGE proteins promote
tumor development and providing a rationale for combining
anti-MAGE therapy with cytotoxic regimens, which to our
knowledge has not been reported previously.
RESULTS
Downregulation of MAGE-C2 induces apoptosis in A375 human
melanoma cells
To investigate the functions of MAGE-C2 in human melanoma
cells, we transduced A375 cell line with tetracycline-respon-
sive scrambled or MAGE-C2 short hairpin RNA (shRNA), also
encoding red fluorescent protein (TurboRFP). Transduced
A375 cells treated with doxycycline express RFP (Figure 1a).
Decreased MAGE-C2 expression correlated well with RFP
expression in A375 cells expressing MAGE-C2 shRNA. Cells
transduced with MAGE-C2 shRNA and expressing RFP (red)
exhibit only one-third the intensity of MAGE-C2 (green)
compared with RFP-negative cells or scrambled shRNA-trans-
duced RFP-positive cells (Figures 1a and b; data not shown).
RFP-positive single-cell clones were selected and MAGE-C2
knockdown in these clones was confirmed by immunoblotting
(Figure 1c). Downregulation of MAGE-C2 induces increased
apoptosis in A375 cells (Figure 1d). Cells expressing MAGE-
C2 shRNA show 7.58% apoptosis as compared with 1.1%
apoptosis in scrambled shRNA cells.
Downregulation of MAGE-C2 induces apoptosis in low-passage
human melanoma cultures
We next examined low-passage cells derived from human
metastatic melanomas and found that 9 out of 13 (69%) short-
term melanoma cultures derived from melanoma metastases
(MRA-1–13) expressed MAGE-C2; MRA-5, -10, and -11
expressed high levels of MAGE-C2, MRA-7 and -13 expressed
intermediate levels, and MRA-2, -6, -8, and -12 expressed low
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Figure 1. Downregulation of melanoma-associated antigen-encoding (MAGE)-C2 induces apoptosis in A375 melanoma cells. A375 cells were transduced with
lentiviruses expressing tetracycline-responsive scrambled or MAGE-C2 short hairpin RNA (shRNA) and red fluorescent protein (RFP). Transduction efficiency was
assessed by RFP expression and stained for MAGE-C2 (green). (a) A375 cells expressing MAGE-C2 shRNA before selection with puromycin were treated with
0.5mg ml1 doxycycline for 72hours and showed decreased MAGE-C2 expression (green) in RFP-positive cells. Bar¼50mm. (b) A histogram of MAGE-C2 intensity
in RFP-expressing versus non-expressing cells using the NIS Elements software, *Po0.05. (c) Single-cell clones were selected on the basis of RFP and MAGE-C2
expression. MAGE-C2 expression in a representative clone is shown by immunoblotting after 72hours of 0.5mg ml1 doxycycline treatment. (d) Downregulation of
MAGE-C2 induces apoptosis in A375 cells as analyzed by TUNEL assay, *Po0.02.
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levels (Figure 2a), indicating that MAGE-C2 is commonly
expressed in advanced melanomas. MRA-13 cells were
transduced with lentiviruses encoding tetracycline-responsive
scrambled or MAGE-C2 shRNA. MRA-13 cells expressing
MAGE-C2 shRNA exhibit diminished expression of MAGE-
C2 (Figure 2b). Knockdown of MAGE-C2 induced apoptosis in
40% of MRA-13 cells as shown by TUNEL stain (green)
(Figure 2c–e). TUNEL and MAGE-C2 co-staining showed
that most of the cells positive for TUNEL also had lower
expression of MAGE-C2 (faint pseudocolor pink) (Figure 2c–e).
Similar results were also observed in MRA-11 cells (data not
shown). In accordance with our results in A375 melanoma
cells, these data show that loss of MAGE-C2 induces
apoptosis in MRA-13 melanoma cells, confirming that
MAGE-C2 expression is associated with increased survival of
melanoma cells.
MAGE-C2 knockdown decreases low-passage melanoma tumor
xenograft growth in athymic nude mice
To determine the effect of the downregulation of MAGE-C2 in
tumor xenografts, MRA-13 cells, transduced with lentiviruses
encoding tetracycline-responsive scrambled or MAGE-C2
shRNA, were injected into athymic nude mice. One week
after tumor inoculation, groups of mice (seven mice per group)
were fed either water or doxycycline solution. Growth of
MRA-13 MAGE-C2 shRNA tumors were stunted in the group
of mice drinking doxycycline solution in water compared with
mice on the doxycycline-free diet (Figure 3a). Tumor volume
in the doxycycline treatment group was 50% lower at week 3,
2 weeks after initiation of doxycycline treatment, and 41%
lower after 6 weeks, at the termination of the experiment
(Figure 3a). Figure 3b compares the growth of xenografts
expressing shMAGE-C2 or scrambled shRNA with their
counterparts without doxycycline treatment. Linear trend lines
for these experiments show a 49% decrease in MRA-13
MAGE-C2 shRNA tumor volume with doxycycline treatment
(coefficient of determination R2¼0.49) compared with a 9%
decrease in MRA-13 scrambled shRNA tumor volume with
doxycycline treatment (coefficient of determination R2¼0.09).
MAGE-C2 expression was assessed in MRA-13 tumors
collected from all the groups by immunohistochemistry and
immunoblotting. Figure 3c and d confirms the diminished
expression of MAGE-C2 in MRA-13 tumor tissue collected
from the MAGE-C2 shRNA group being fed doxycycline.
No difference was observed in MAGE-C2 expression in
MRA-13 tumors collected from scrambled shRNA groups with
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Figure 2. Short-term cell cultures of metastatic melanomas express melanoma-associated antigen-encoding (MAGE)-C2, and downregulation of MAGE-C2
induces apoptosis. (a) Immunoblotting detects variable expression of MAGE-C2 in 9 of 13 MRA cells, low-passage cultures from human melanoma metastases.
(b) Immunoblotting shows that doxycycline-responsive MAGE-C2 short hairpin RNA (shRNA) downregulates MAGE-C2 in MRA-13 cells. (c) Photomicrographs
show MAGE-C2 downregulation (faint pseudocolor pink) in MRA-13 cells is associated with apoptosis, as measured by TUNEL staining (green). Control shRNA
cells show high MAGE expression and only rare apoptotic cells. Inset shows TUNEL-positive cells magnified 60. The arrows point to TUNEL positive (apoptotic)
cells. Bar¼ 50mm. (d) MAGE-C2 expression was determined by quantitative immunofluorescence (pseudocolor pink). The histogram shows that MAGE-C2
expression is decreased in shMAGE-C2-expressing cells as opposed to cells expressing scrambled shRNA, confirming MAGE-C2 knockdown, *Po0.01. (e) The
histogram compares TUNEL-positive (green) cells as a percentage of total 406-diamidino-2-phenylindole-positive cells in control (scrambled) and MAGE-C2
shRNA-expressing cells. The histogram shows that TUNEL staining in MRA-13 cells is increased with MAGE-C2 knockdown as compared with scrambled shRNA,
*Po0.02.
N Bhatia et al.
MAGE-C2 Induces Apoptosis and DNA Repair
www.jidonline.org 761
or without doxycycline. Similar results were observed with
tumor xenografts of MRA-11 cells (data not shown). TUNEL
staining in xenograft tumors showed increased apoptosis in
tumors with MAGE-C2 knockdown, as was seen with in vitro
cultures (Figure 3e). These results demonstrate and corroborate
our in vitro results that MAGE-C2 promotes survival of
melanoma cells both in vitro and in vivo.
MAGE-C2 expression increases and induces phosphorylation
of KAP1
Phosphorylation of KAP1-Ser824 can be induced by DNA
damage and is essential for DNA repair. To study the effect of
MAGE-C2 downregulation on KAP1-Ser824 phosphorylation,
A375 cells transduced with scrambled or MAGE-C2 shRNA
were treated with doxycycline in conjunction with doxorubi-
cin, a DNA-damaging agent. As demonstrated in Figure 4a,
MAGE-C2 knockdown in A375 cells resulted in reduced
phosphorylation of KAP1-Ser824. A375 cells expressing
scrambled shRNA and treated with doxorubicin did not show
any difference in levels of phospho-KAP1-Ser824. Immuno-
precipitation with KAP1 antibody and immunoblotting for
phospho-KAP1-Ser824 showed lower levels of phospho-
KAP1-Ser824 in A375 cells with MAGE-C2 downregulation,
even without doxorubicin-induced DNA damage (data not
shown). Overall, our data suggest that inhibition of MAGE-C2
expression causes a reduction in the basal levels of
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Figure 3. Melanoma-associated antigen-encoding (MAGE)-C2 knockdown reduces growth of MRA-13 melanoma xenografts in athymic nude mice. Four-week-
old athymic nude mice, seven mice per group, were injected with MRA-13 cells expressing scrambled or MAGE-C2 short hairpin RNA (shRNA) and were given
either water or 2 mg ml 1 doxycycline solution. The xenograft experiment was terminated 6 weeks later or when tumors reached a volume of 1,400 mm3.
(a) Tumor growth decreased by 40% in MAGE-C2 shRNA mice treated with doxycycline (MAGE-C2 downregulation) compared with no doxycycline treatment.
(b) Linear trend lines compare growth of xenografts expressing MAGE-C2 and scrambled shRNA with their counterparts without doxycycline treatment.
MAGE-C2 shRNA tumors show a downward trend compared with scrambled shRNA tumors. (c) Immunoperoxidase staining shows that MAGE-C2 expression
in xenograft tumors is decreased by doxycycline-dependent induction of MAGE-C2 shRNA. Bar¼ 50mm. (d) Downregulation of MAGE-C2 is observed by
immunoblotting in MAGE-C2 shRNA tumors after doxycycline treatment. (e) Apoptosis was detected in xenograft tumor sections by TUNEL assay. The histograms
show increase in apoptosis in tumors with MAGE-C2 downregulation, *Po0.05.
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KAP1-Ser824 phosphorylation and decreases KAP1-Ser824
phosphorylation in response to doxorubicin-induced DNA
double-strand breaks (DSBs).
To further validate the effect of MAGE-C2 expression on
phosphorylation of KAP1-Ser824, MAGE-C2 was ectopically
expressed in HEK293T cells. In accordance with the results of
MAGE-C2 knockdown in A375 cells, overexpression of
MAGE-C2 induced phosphorylation of KAP1-Ser824, whereas
no effect was observed with an empty vector (Figure 4b). As
shown in Figure 4b, MAGE-C2 expression also enhanced
doxorubicin-induced phosphorylation of KAP1-Ser824.
These results demonstrate that MAGE-C2 expression induces
phosphorylation of KAP1-Ser824 and also enhances DNA
damage–induced phosphorylation of KAP1-Ser824. As phos-
phorylation of KAP1-Ser824 is required for DNA damage
repair, these results further suggest that MAGE-C2 expression
may promote DNA repair.
MAGE-C2-induced KAP1 phosphorylation is ATM
kinase–dependent
ATM kinase acts as a key regulator of the DNA repair cascade
(Roos and Kaina, 2006; Shanbhag et al., 2010). In response to
DNA damage, ATM is activated and autophosphorylated on
Ser1981 and initiates a cascade of phosphorylation events,
including p53, leading to DNA repair or apoptosis (Goodarzi
et al., 2008). Similar to p53 phosphorylation, ATM-induced
phosphorylation of KAP1-Ser824 is an early event in DNA
repair, inducing relaxation of heterochromatin, which is
necessary for access to sites of DNA breaks and critical for
progression of the DNA damage repair response (White et al.,
2006; Goodarzi et al., 2009; Smeenk and Lohrum, 2010).
To determine whether MAGE-C2-induced phosphorylation
of KAP1-Ser824 is dependent on ATM kinase, we inhibited
ATM kinase activity in HEK293T cells expressing ectopic
MAGE-C2. For inhibition of ATM kinase activity, we used
KU55933 (2-(4-morpholinyl)-6-(1-thianthrenyl)-4H-pyran-4-
one), a potent and selective inhibitor of ATM kinase. As
exhibited in Figure 5a, treatment with KU55933 reduces
MAGE-C2- and doxorubicin-induced phosphorylation of
KAP1-Ser824, whereas KAP1 expression remains constant.
To confirm inhibition of ATM kinase activity by KU55933, we
probed for phospho-p53-Ser15, another substrate of ATM
kinase. Figure 5a confirms inhibition of p53 phosphorylation
at Ser15 in response to KU55933, validating the inhibition of
ATM kinase activity. No change in p53 expression was
observed. These results demonstrate that MAGE-C2-induced
phosphorylation of KAP1-Ser824 is ATM kinase–dependent.
To confirm the effect of ATM kinase on MAGE-induced
phosphorylation of KAP1-Ser824, we inhibited ATM kinase by
specific small interfering RNA (siRNA). HEK293T cells, ecto-
pically expressing empty vector or MAGE-C2, were trans-
fected with ATM kinase siRNA and treated with doxorubicin.
Figure 5b shows that siRNA-mediated inhibition of ATM
kinase results in loss of MAGE-C2- and doxorubicin-induced
phospho-KAP1-Ser824. These results confirm our results with
ATM kinase inhibitor KU55933.
Interaction of MAGE-C2 and KAP1 increases ATM
kinase–dependent phosphorylation of KAP1-Ser824
To determine whether MAGE-C2 effects on KAP1-Ser824
phosphorylation require direct interaction between MAGE-C2
and KAP1, we used mutant MAGE-C2 (MAGE-C2L152A L153A),
which does not bind to KAP1 (Doyle et al., 2010). Figure 5b
shows that, in response to MAGE-C2L152A L153A and in the
presence of doxorubicin, increase in KAP1-Ser824 phosphor-
ylation is comparable to the vector plasmid, which also has
been confirmed in Figure 5c. These results indicate that direct
binding of MAGE-C2 to KAP1 is required for this effect. We
found that similar experiments using a deletion mutant KAP1,
which lacks the RBCC region necessary for MAGE binding,
were not interpretable because RBCC-deleted KAP1 was
spontaneously and strongly phosphorylated on Ser824, regard-
less of the presence of MAGE-C2 or doxorubicin. As the
MAGE-binding region and Ser824 are in different domains of
KAP1, this result suggests that the RBCC region has an
autoinhibitory effect on KAP1-Ser824 phosphorylation that
can be relieved by deletion of the RBCC region or by binding
of MAGE-C2.
Finally, to determine whether in the presence of MAGE-C2
KAP1 can form complexes with ATM kinase, we expressed
plasmid-encoded FLAG-tagged KAP1 and MAGE-C2 in
HEK293T cells and immunoprecipitated protein lysates with
ATM kinase antibody. Immunoblotting with anti-FLAG showed
that both KAP1 and MAGE-C2 immunoprecipitated with ATM,
in the presence of doxorubicin, indicating that KAP1 and ATM
can form complexes in the presence of MAGE-C2 (Figure 5c).
Taken together, these data show that, in the presence of
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MAGE-C2, KAP1 complexes with ATM, enhancing ATM-
dependent phosphorylation of KAP1-Ser824, a critical step
in the cellular response to DNA DSBs.
MAGE-C2 expression promotes DNA repair
DNA damage results in rapid phosphorylation of H2A.X at
Ser139. To assess the effect of MAGE-C2 on DNA damage
markers, A375 cells expressing scrambled or MAGE-C2
shRNA were treated with doxycycline for 96 hours and stained
for phospho histone H2A.X-Ser139. Photomicrographs in
Figure 6a demonstrate an increase in phospho-H2A.X in
A375 cells with downregulation of MAGE-C2. A375 cells
expressing shMAGE-C2 and treated with doxycycline show
34% cells positive for phospho-H2A.X-Ser 139 as compared
with 5% in cells expressing scrambled shRNA (Figure 6b).
To assess DNA repair in response to DNA damage, we used
an assay that utilizes green fluorescent protein (GFP) as a
reporter system and I-Sce I endonuclease to introduce defined
DNA DSBs in U-2 OS cells (Pierce et al., 1999). An 18-bp
I-Sce I site and linker was inserted within a copy of the GFP
gene, inactivating it. When cleaved, a homologous repair
event with a linked donor GFP gene fragment restores
functional GFP expression, causing cells to fluoresce green.
Figure 6c depicts co-expression of MAGE-C2 and GFP and
also shows graphically that GFP expression is higher in
MAGE-C2-positive cells compared with MAGE-C2-negative
cells. As demonstrated in Figure 6d, 89% more cells undergo
DNA repair in the presence of ectopically expressed MAGE-
C2 than do cells expressing empty vector. Figure 6e validates
the expression of MAGE-C2 in U-2 OS cells by immunoblot-
ting. These data demonstrate that MAGE-C2 expression
promotes repair of DNA DSBs.
DISCUSSION
MAGE proteins are expressed in many types of human tumors
including at least 50% of advanced malignant melanomas
(Barker and Salehi, 2002). Although normal melanocytes and
most melanocytic nevi do not express MAGE proteins, MAGE
expression in melanomas is associated with advanced and
aggressive growth (Hofbauer et al., 1997; Basarab et al., 1999;
Riker et al., 2008). Gene expression profiling shows an
increase in MAGE-A3/6 expression over the entire range of
melanoma thickness, a factor that correlates with poorer
prognosis (Riker et al., 2008). MAGE proteins are important
prognostic factors and have been associated with metastases,
poor tumor differentiation, and clinical relapse in melanoma;
however, the mechanisms behind these associations have not
been completely determined (Hoek et al., 2004; Bellati et al.,
2007; Svobodova et al., 2011).
The work presented here confirms the effects of MAGE-C2
on the viability of A375 cells, a widely used established cell
line, and with low-passage human melanoma cells from
metastases, using both in vitro and in vivo approaches. Here,
our work with doxycycline-inducible shRNA encoded in
integrated lentiviruses shows that established human mela-
noma xenografts can respond to MAGE-C2 knockdown
triggered by a systemically administered agent.
We and others have previously reported that MAGE proteins
promote the growth and survival of tumor cells, at least in part,
by suppressing p53 and apoptosis (Monte et al., 2006; Yang
et al., 2006, 2007; Liu et al., 2008). More recently, Doyle
et al. (2010) confirmed and extended our results, showing that
MAGE proteins bind to KAP1 and enhance the E3 ubiquitin
ligase activity of KAP1, causing p53 polyubiquitination and
degradation. Most recently, we have shown that MAGE
proteins are master regulators of KRAB domain containing
zinc finger transcription factors (KZFs), the largest group of
transcription factors in vertebrates (Xiao et al., 2011). KZFs
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Figure 5. Melanoma-associated antigen-encoding (MAGE)-C2 binds to KAP-1
and induces ataxia-telangiectasia–mutated (ATM) kinase–dependent
phosphorylation of KAP1-Ser824. (a) HEK293T cells, ectopically expressing
MAGE-C2, were treated with doxorubicin and KU55933, a specific ATM
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transfected with ATM kinase small interfering RNA (siRNA) and treated with
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induced as well as DNA damage–induced phosphorylation of KAP1-Ser824,
confirming the effect of KU55933. (c) Immunoblotting shows that wild-type
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require KAP1 for gene repression and their targets include
many oncogenes and tumor suppressors.
KAP1 is critical for DNA DSB repair. In response to DNA
damage, ATM kinase is activated and phosphorylates
KAP1-Ser824. Phosphorylated KAP-Ser824 localizes to DNA
damage foci and causes chromatin relaxation required for
access by DNA repair proteins. Substitution of mutated
KAP1S824A completely aborts the repair response and renders
cells hypersensitive to DNA damage (White et al., 2006;
Goodarzi et al., 2008). After the DNA is repaired, KAP1-
Ser824 is dephosphorylated, causing chromatin condensation.
We report here a function of MAGE, which to our knowl-
edge has not been reported previously, that induces ATM
kinase–dependent phosphorylation of KAP1-Ser824 and
actively promotes DNA repair. Previous studies and our
current data support an emerging model in which Class I
MAGE expression contributes to tumor growth and survival by
favoring DNA repair over apoptosis. As proliferation by
neoplastic cells can by itself induce DNA damage, MAGE
expression may provide a growth advantage in accordance
with clinical observations that MAGE expression is associated
with tumor progression and aggressive growth (Svobodova
et al., 2011). This concept also fits nicely with in vitro and
in vivo observations that Class I MAGE expression is
associated with resistance to chemotherapy. We also suggest
that MAGE suppression, which will render tumor cells
sensitive to DNA damage, in combination with DNA-
damaging agents may enhance tumor response to therapy.
MATERIALS AND METHODS
Tissue culture
A375 melanoma cells and Human Embryonic Kidney 293T
(HEK293T) cells were obtained from ATCC (Manassas, VA). MRA
melanoma cells, low-passage cultures derived from metastatic
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Figure 6. MAGE-C2 downregulation induces DNA damage, whereas melanoma-associated antigen-encoding (MAGE)-C2 expression induces DNA damage
repair. (a) A375 melanoma cells expressing scrambled or MAGE-C2 short hairpin RNA (shRNA) and treated with doxycycline were stained for phospho histone
H2A.X-Ser139, a marker for DNA damage. Fluorescent photomicrographs show increased expression of phospho histone H2A.X-Ser139 in A375 cells with
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melanoma patients, were provided by Dr Mark R. Albertini. Cells
were propagated in DMEM medium supplemented with 10%
tet-system-approved fetal bovine serum (Clontech, Mountain View,
CA) and 1% penicillin–streptomycin.
Transfections and lentiviral transduction
Tetracycline-responsive TRIPZ shRNAmir, MAGE-C2 or scrambled,
and the Trans-Lentiviral packaging system were purchased from Open
Biosystems (ThermoFisher Scientific, Huntsville, AL). Lentiviruses
were produced, as per manufacturer’s recommendations, and con-
centrated with Lentivirus Concentrator (Clontech). A375 and MRA
cells were transduced with concentrated lentiviruses expressing
scrambled or MAGE-C2 shRNA and selected with puromycin.
Transduction efficiency, determined by expression of TurboRFP,
which is also encoded by the lentivirus vector, was B70% in A375
cells and B90–100% in MRA-13 cells. MRA-13 cultures were used
as bulk cultures, whereas single-cell clones of transduced A375 cells
were selected on the basis of inducible RFP expression. MAGE-C2
knockdown was confirmed by immunoblotting. HEK293T cells
were transfected with vector, MAGE-C2, or mutant MAGE-C2 by
the calcium phosphate method and ATM 472 siRNA (Dharmacon,
Lafayette, CO) by Lipofectamine 2000 (Life Technologies, Grand
Island, NY).
Immunoprecipitations and immunoblotting
A375 and MRA cells, transduced with scrambled or MAGE-C2
shRNA, were treated with doxycycline and collected after 72 hours.
HEK293T cells were transfected with empty plasmid, MAGE-C2, or
mutant MAGE-C2-expression plasmid. Protein lysates were immuno-
precipitated with ATM antibody (Abcam, Cambridge, MA). The
expression of MAGE-C2, Actin (Santa Cruz Biotechnology, Santa
Cruz, CA), phospho-KAP1, KAP1 (Novus Biologicals, Littleton, CO),
M2 FLAG (Sigma-Aldrich, St Louis, MI), and ATM (Abcam) was
analyzed by immunoblotting. Density analysis was performed using
ImageJ software (National Institutes of Health, Bethesda, MD) and
was calculated for loading of the controls as actin or total protein
expression for phosphorylated proteins. Density of the bands is shown
as numbers under the blots.
Cytostaining and TUNEL assay
A375 cells, transduced with lentivirus encoding scrambled or MAGE-
C2 shRNA and treated with 0.5mg ml 1 doxycycline for 72 hours,
were stained with MAGE-C2 antibody (Santa Cruz Biotechnology) or
phospho histone H2A.X (Cell Signaling, Danvers, MA) and FITC-
labeled secondary antibody (Jackson ImmunoResearch Laboratories,
West Grove, PA). MRA-13 and A375 melanoma cells, transduced
with lentivirus encoding scrambled or MAGE-C2 shRNA and treated
with doxycycline for 96 hours, were stained for TUNEL using the
FITC-labeled DeadEnd Fluorometric TUNEL System (Promega, Madi-
son, WI). These cells were co-stained with MAGE-C2 (Santa Cruz
Biotechnology). Mouse MRA-13 tumor xenograft sections were also
stained with TUNEL. Quantitative analysis of TUNEL stain and
fluorescent MAGE-C2 or phospho-H2AX was carried out using NIS
Elements software (Nikon, Melville, NY).
Athymic nude mice xenografts
MRA-13 cells, transduced with lentivirus encoding tetracycline-
responsive scrambled or MAGE-C2 shRNA and selected with
puromycin, were used for xenograft studies. Transduction efficiency
was 90–100% as detected by RFP expression after treatment with
doxycycline. Four million MAGE-C2 or scrambled shRNA tumor cells
were injected subcutaneously into 4-week-old athymic nude mice
(Harlan Laboratories, Indianapolis, IN). A week later, half of the mice
were given 2 mg ml 1 doxycycline in drinking water, with seven
mice per group. The xenograft experiment was terminated 6 weeks
later or when tumors were 1,400 mm3 in volume, as per protocol.
Immunohistochemical staining
Tumors collected from athymic nude mice xenografts were fixed in
formalin and embedded in paraffin. Paraffin sections were stained
with MAGE-C2 antibody and developed by 3,3-diaminobenzidine
(Sigma-Aldrich, St. Louis, MO).
ATM kinase inhibitor (KU55933) treatment
HEK293T cells, transfected with empty vector or MAGE-C2 expres-
sion plasmid, were treated with KU55933 ATM kinase inhibitor
(Tocris Biosciences, Ellisville, MO) for 24 hours. Cells were collected
and lysed as mentioned before. The expression of MAGE-C2,
phospho-KAP1, KAP1, phospho p53, p53, and actin was evaluated
by immunoblotting.
DNA damage and repair assay
U-2 OS cells, containing an integrated modified gene for GFP, were
used to measure DNA damage repair (Pierce et al., 1999). Cells were
co-transfected with I-SceI pCbASce plasmid and empty vector or
MAGE-C2. After 48 hours, cells were immunostained for MAGE-C2
expression (red). The expression of MAGE and GFP was enumerated
and compared, including measurement of staining intensity using NIS
Elements software.
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